Japan Approval for FRUZAQLA | 24-Sep-2024 | 08:00 | RNS |
Total Voting Rights | 30-Aug-2024 | 09:30 | RNS |
Update on Fruquintinib for Gastric Cancer in China | 30-Aug-2024 | 07:00 | RNS |
Standard form for notification of major holdings | 22-Aug-2024 | 09:30 | RNS |
LTIP and Share Option Scheme | 06-Aug-2024 | 10:00 | RNS |
2024 Interim Results and Business Updates | 31-Jul-2024 | 12:00 | RNS |
Blocklisting Six Monthly Return | 28-Jun-2024 | 09:30 | RNS |
Total Voting Rights | 28-Jun-2024 | 09:30 | RNS |
HUTCHMED to Announce 2024 HY Financial Results | 26-Jun-2024 | 09:30 | RNS |
European Commission Approval for FRUZAQLA | 24-Jun-2024 | 07:00 | RNS |
Total Voting Rights | 31-May-2024 | 09:30 | RNS |
Retirement of Chairman and new Chairman appointed | 17-May-2024 | 15:00 | RNS |
Result of AGM | 10-May-2024 | 13:00 | RNS |
Directorate Change | 08-May-2024 | 09:30 | RNS |
Positive CHMP Opinion for Fruquintinib | 26-Apr-2024 | 13:30 | RNS |
Currency | UK Pounds |
Share Price | 298.00p |
Change Today | -8.00p |
% Change | -2.61 % |
52 Week High | 352.00 |
52 Week Low | 192.40 |
Volume | 71,061 |
Shares Issued | 871.47m |
Market Cap | £2,596.98m |
RiskGrade | 226 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
Time | Volume / Share Price |
16:35 | 15,444 @ 298.00p |
16:35 | 185 @ 298.00p |
16:35 | 14 @ 298.00p |
16:35 | 130 @ 298.00p |
16:35 | 306 @ 298.00p |
You are here: research